Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 15, 1998The Prostate

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

View Full Paper
Ask AI
Bookmark
Share

Authors

BTB.A. TjoaCharles River Laboratories (United States)SSS.J. SimmonsNorthwest Biotherapeutics (United States)VBVictoria BowesAbbotsford Veterinary Clinic

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tjoa et al. (1998) studied this question.

synapsesocial.com/papers/6a829fa55011f468996cfef0https://doi.org/10.1002/(sici)1097-0045(19980615)36:1<39::aid-pros6>3.0.co;2-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides1997 · 127 citations
  2. 2Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine1992 · 405 citations
  3. 3Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients1997 · 57 citations
  4. 4Prostatic Carcinoma1979 · 189 citations
  5. 5Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen1996 · 394 citations